Newest | These 20 best selling drugs

1

Hospital market, Top 20 drugs

According to the full-year data information of the PDB (PDB) in 2020, affected by the new crown epidemic, the market sales of sample hospitals in my country's key cities in 2020 will be 221.

In the past year, due to the impact of the new crown epidemic, the number of outpatient visits in hospitals has dropped sharply.

In terms of breakdown, the drug categories with the largest decline are neurologic medications, anti-infective medications, and cardiovascular medications, all with a decline of more than 20%; the smallest decline is anti-tumor drugs, which is about 4%.

In my country's overall sample market, there are only 83 drugs with sales of more than 500 million in 2020, and this figure is still 111 in 2019.

Specifically, in 2020, the top 20 drugs in the sample hospitals' sales are as follows:

Human albumin, sodium chloride injection, dezocine injection, pegylated recombinant human granulocyte stimulating factor injection, meropenem for injection, bevacizumab injection, cefoperazone sodium and sulbactam sodium for injection, Osimertinib mesylate tablets, trastuzumab for injection, iodixanol injection, intravenous human immunoglobulin (pH4), tacrolimus capsules, rituximab injection, recombinant human Thrombopoietin injection, pemetrexed disodium for injection, piperacillin sodium and tazobactam sodium for injection, docetaxel injection, paclitaxel for injection (albumin-bound type), oxaliplatin for injection , Butylphthalide and Sodium Chloride Injection.

2

8 major varieties, sales increase

Among the top 20 drugs in sales, there are 8 drugs.

Among them, the largest increase was osimertinib mesylate tablets.

Osimertinib mesylate is AstraZeneca's third-generation lung cancer targeted drug, with global sales of US$3.

In October 2018, osimertinib mesylate (Teresa) was included in medical insurance through special negotiations on anticancer drugs.

Subsequently, osimertinib successfully renewed its contract and entered the 2019 edition of the National Medical Insurance Negotiation Catalog.

It is worth noting that in September 2019, osimertinib was approved for the second indication for local late or metastasis with epidermal growth factor receptor exon 19 deletion or exon 21 (L858R) substitution mutation First-line treatment for adult patients with sexual non-small cell lung cancer.

3

12 varieties, some decline

Among the remaining 12 drugs that have declined in sales, the largest drop was paclitaxel for injection (albumin-bound), which dropped by as much as 25%.

Paclitaxel for injection (albumin-binding type) is an anti-microtubule drug used to treat metastatic breast cancer that has failed combined chemotherapy or breast cancer that recurs within 6 months after adjuvant chemotherapy.

Paclitaxel for injection (albumin-binding type), as the top tumor drug in sales, was included in the second batch of national organization drug procurement due to three or more manufacturers.

In March 2019, Xinji’s paclitaxel for injection (albumin-binding type) was suspended by the State Food and Drug Administration because its production facilities did not meet the requirements of my country’s GMP, and the Joint Procurement Office subsequently announced its cancellation of the eligibility.

In the second round of national centralized procurement, the procurement cycle of paclitaxel for injection (albumin-bound type) was two years.

4

Sample hospital, top 10 pharmaceutical companies

According to the latest data in 2020, the top 10 pharmaceutical companies in sample hospital sales are: AstraZeneca, Pfizer, Jiangsu Hengrui, Roche, Yangtze River Pharmaceutical, Novartis, CSPC, Bayer, Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical Industry group.

Among the top 10 pharmaceutical companies, only two have maintained positive growth.
They are CSPC and Qilu Pharmaceutical-Qilu Pharmaceutical's revenue in 2020 reached 4.
69 billion yuan, compared with 4.
27 billion yuan in 2019.
Increased revenue, an increase of 9.
8%.

The top three pharmaceutical companies, AstraZeneca, Pfizer, and Jiangsu Hengrui, have revenues of 8.
86 billion yuan, 7.
72 billion yuan, and 6.
9 billion yuan, respectively, and their leading advantages are obvious.

In general, among the top 10 pharmaceutical companies, domestic pharmaceutical companies and multinational pharmaceutical companies each occupy five seats, and the overall ranking of multinational pharmaceutical companies is high.
From the perspective of total revenue, the total revenue of domestic pharmaceutical companies is 26.
34 billion yuan, and the total revenue of multinational pharmaceutical companies is 33.
64 billion yuan.

However, compared with foreign companies, the performance growth rate of domestic pharmaceutical companies still has a good performance.
Affected by factors such as volume purchases, the revenue of many foreign companies has declined.
Among them, Pfizer's revenue in 2020 has dropped by 20.
6% compared with 2019, which is a significant drop.

As time progresses, in the public hospital market, what will the variety and ranking of domestic and foreign pharmaceutical companies look like? We will wait and see.